SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The company's SSi Mantra surgical robotic system installations rose 30.4% to 30 during the quarter, reflecting strong demand for its cost-effective robotic surgery solutions. Gross profit increased 20% to $7.1 million, with a gross margin of 50.9%, while the net loss widened to $2.7 million from $0.3 million in the prior-year quarter.
The robust performance extended to the first half of the year, with revenue surging 65.6% to $25 million and SSi Mantra installations climbing 47.4% to 56. As of June 30, the company had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures using the SSi Mantra as of June 30, including 175 telesurgeries, and completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India.
These results come as SS Innovations awaits regulatory approvals that could significantly broaden its market reach. The company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, it believes it can obtain European Union CE marking certification by the end of 2026. Achieving these milestones would allow SS Innovations to enter the U.S. and European markets, potentially transforming the competitive landscape of surgical robotics, which is currently dominated by established players.
The financial performance and strategic progress highlight the growing importance of affordable robotic surgery systems in global healthcare. SS Innovations aims to make robotic surgery accessible to a larger segment of the population, particularly in emerging markets where cost has been a barrier. The company's telesurgery capabilities also demonstrate the potential for remote surgical procedures to expand access to specialized care, especially in underserved regions.
Investors and industry analysts view these developments as positive indicators of SS Innovations' growth trajectory. The company's focus on innovation and expansion aligns with broader trends in minimally invasive surgery, which is increasingly favored for its potential to reduce patient recovery times and healthcare costs. As regulatory approvals progress, the company could see accelerated adoption of its technology, further driving revenue growth and market share gains.
Despite the expanded net loss in the second quarter, largely due to increased investment in research and development and commercial activities, the company's strong revenue growth and cash position provide a solid foundation for future operations. With a clear path to regulatory milestones and a growing installed base, SS Innovations is positioning itself as a key player in the global surgical robotics market.
